Latest News for: cdx

Edit

Natera Submits Signatera™ CDx PMA to FDA

Business Wire 02 Feb 2026
Food and Drug Administration (FDA) for Signatera™ CDx for detection of molecular residual disease ...
Edit

Milestone in Precision Oncology! Burning Rock Dx’s Breast Cancer NGS CDx Kit Enters the CMDE Priority Review Channel (Burning Rock Biotech Ltd)

Public Technologies 26 Jan 2026
) Milestone in Precision Oncology! Burning Rock Dx's Breast Cancer NGS CDx Kit Enters the CMDE Priority Review Channel ... As the first breast cancer NGS companion diagnostic (CDx) kit in China, this ...
Edit

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination ...

Times Argus 22 Jan 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Jan 22, 2026-- ....
Edit

Guardant Health Receives FDA Approval for Guardant360� CDx as Companion Diagnostic for BRAFTOVI� (encorafenib) Combination ...

Business Wire 22 Jan 2026
Food and Drug Administration (FDA) has approved Guardant360� CDx as a companion diagnostic to ...
Edit

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Nasdaq Globe Newswire 21 Dec 2025
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX. TLX, NASDAQ. TLX, “Telix”) today provides a precision medicine portfolio update in relation to ... .
Edit

Pillar Biosciences Announces Final CMS Pricing Determination for oncoReveal® CDx

Polk County Itemiser-Observer 02 Dec 2025
... finalized its pricing determination for oncoReveal CDx.
Edit

Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Repotrectinib with NTRK Fusion-Positive Solid-Tumors (Chugai Pharmaceutical Co Ltd)

Public Technologies 20 Nov 2025
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Repotrectinib with NTRK Fusion-Positive Solid-Tumors ... About FoundationOne CDx Cancer Genomic Profile.
Edit

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with

The Eagle-Tribune 19 Nov 2025
TLX, “Telix”) today announces results from the ZIRCON-X ...
Edit

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

Nasdaq Globe Newswire 19 Nov 2025
TLX, “Telix”) today announces results from the ZIRCON-X study which finds that almost half of all patients ...
  • 1

Article Search

tools
×
×
×
×